Medicago Inc. and Mitsubishi Chemical Holdings Corporation Enter into a Collaboration to Develop a Next Generation Technology

   Medicago Inc. and Mitsubishi Chemical Holdings Corporation Enter into a
  Collaboration to Develop a Next Generation Technology for Plant Production

PR Newswire

QUEBEC CITY, Jan. 28, 2013

QUEBEC CITY, Jan.  28, 2013 /PRNewswire/  - Medicago Inc.  (TSX: MDG)  (OTCQX: 
MDCGF), a biopharmaceutical company focused on developing highly effective and
competitive vaccines  based  on  proprietary  manufacturing  technologies  and 
Virus-Like Particles (VLPs), today announced the execution of a  collaboration 
agreement with Mitsubishi Chemical Holdings Corporation ("MCHC") to develop  a 
next generation  technology  for  plant production.  The  objectives  of  the 
collaboration  are  to  evaluate  MCHC's   Plant  Factory  System,  a   closed 
cultivation system,  to  produce  Nicotiana  Benthamiana  plants  for  protein 
production using Medicago's technologies.

"Our goal is  to develop a  highly effective, closed  plant production  system 
with  our  partner,  Mitsubishi,"  said  Andy  Sheldon,  President  and  Chief 
Executive Officer of Medicago. "This system  would be designed to enhance  our 
capacity  and  further  decrease  operating  costs,  whilst  facilitating  new 
applications of  Medicago's  technology. We  are  pleased to  build  upon  our 
existing strategic relationship with Mitsubishi and look forward to continuing
to strengthen the synergies between our two companies."

"We are  pleased  to intensify  our  collaboration with  Medicago  to  further 
combine our  strengths," said  Dr. Seiichi  Kiso, Executive  Officer, Head  of 
Healthcare Solutions  Office  of  MCHC  "Medicago  and  Mitsubishi  have  both 
developed very promising  technologies and  we see  a significant  opportunity 
from joining  the  two  technologies  into a  next  generation  plant  protein 
production platform."

MCHC has developed a Plant Factory System, a closed hydroponic system to  grow 
plants, which is currently used  for industrial scale vegetable production  in 
Japan and other countries. Using solar panels and LED lighting, it is meant to
achieve efficient, clean, safe  and environmentally friendly plant  production 
which is  not dependant  on  weather conditions.  These features  can  provide 
tightly controlled conditions  and reproducibility which  are key elements  to 
ensure reliable  biopharmaceutical  production in  different  geographies  and 

Under the terms of their collaboration agreement, Medicago and MCHC will  work 
together exclusively  for one  year  to evaluate  the potential  of  combining 
MCHC's  Plant  Factory  System   with  Medicago's  plant  protein   production 

About Medicago
Medicago is a clinical-stage biopharmaceutical company developing novel
vaccines and therapeutic proteins to address a broad range of infectious
diseases worldwide. The Company is committed to providing highly effective and
competitive vaccines and therapeutic proteins based on its proprietary VLP and
manufacturing technologies. Medicago is a worldwide leader in the development
of VLP vaccines using a transient expression system which produces recombinant
vaccine antigens in plants. This technology has potential to offer more potent
vaccines with speed and cost advantages over competitive technologies,
enabling the development of a vaccine for testing in approximately one month
after the identification and reception of genetic sequences from a pandemic
strain. This production time frame has the potential to allow vaccination of
the population before the first wave of a pandemic, and supply large volumes
of vaccine antigens to the world market. Medicago also intends to expand
development into other areas such as biosimilars and biodefense products where
the benefits of our technologies can make a significant difference. Additional
information about Medicago is available at

About Mitsubishi Chemical Holdings Corporation
Mitsubishi Chemical Holdings Corporation (MCHC) is a Japan's leading
integrated chemical company, and the MCHC Group includes four core operating
companies: Mitsubishi Chemical Corporation, Mitsubishi Tanabe Pharma
Corporation, Mitsubishi Plastics, Inc., and Mitsubishi Rayon Co., Ltd. At the
Group, they serve their customers by using their chemistry-based technology
platforms to develop a wide range of technologies and products in the fields
of performance products, healthcare, and industrial materials. Under the Group
philosophy: "Good Chemistry for Tomorrow", MCHC established a new concept,
KAITEKI, which encompasses sustainability, health, and comfort. The Group aims
to realize a truly sustainable state of comfort, not only for individuals but
also for society and the earth as a whole, by providing their technologies and
products. Further information about MCHC is available on its website:

Forward Looking Statements
This news release includes certain forward-looking statements or
forward-looking information for the purposes of applicable securities laws and
such statements and information are based upon current expectations, which
involve risks and uncertainties associated with Medicago's business and the
environment in which the business operates. Any statements contained herein
that are not statements of historical facts may be deemed to be
forward-looking, including those identified by the expressions "anticipate",
"believe", "plan", "estimate", "expect", "intend", and similar expressions to
the extent they relate to Medicago or its management. The forward-looking
statements are not historical facts, but reflect Medicago's current
expectations regarding future results or events. These forward-looking
statements are subject to a number of risks and uncertainties that could cause
actual results or events to differ materially from current expectations,
including the matters discussed under "Risk Factors and Uncertainties" in
Medicago's Annual Information Form filed on March 29, 2012, with the
regulatory authorities. Medicago assumes no obligation to update the
forward-looking statements, or to update the reasons why actual results could
differ from those reflected in the forward-looking statements.

SOURCE Medicago Inc.


Medicago Inc.
Andy Sheldon
President and CEO
(418) 658-9393

Medicago Inc.
Christina Cameron
Investor Relations
(418) 658-9393 ext. 156
Press spacebar to pause and continue. Press esc to stop.